Patents by Inventor Paul D. Ponath

Paul D. Ponath has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190119395
    Abstract: This disclosure provides combination therapy for treating a subject, such as a subject afflicted with a lung cancer, comprising administering to the subject an anti-fucosyl-GM1 antibody and an anti-CD137 antibody, or antigen-binding portions of either or both.
    Type: Application
    Filed: April 14, 2017
    Publication date: April 25, 2019
    Inventors: Josephine M. CARDARELLI, Daniel E. LOPES de MENEZES, Paul D. PONATH, Bingliang CHEN, Chin PAN
  • Publication number: 20190030162
    Abstract: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.
    Type: Application
    Filed: May 25, 2018
    Publication date: January 31, 2019
    Inventors: Jose F. Ponte, Paul D. Ponath, Michael Rosenzweig
  • Publication number: 20180179282
    Abstract: This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an antibody or an antigen-binding portion thereof that binds specifically to Programmed Death-1 (PD-1) or to Programmed Death Ligand-1 (PD-L1), and an antibody or an antigen-binding portion thereof that binds specifically to C-X-C Chemokine Receptor 4 (CXCR4) or to C-X-C motif chemokine 12 (CXCL12). The disclosure also provides a kit for treating a subject afflicted with a cancer, the kit comprising one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to PD-1 or to PD-L1, one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to CXCR4 or to CXCL12, and instructions for using the antibodies or portions thereof for treating the subject.
    Type: Application
    Filed: June 13, 2016
    Publication date: June 28, 2018
    Inventors: Josephine M. Cardarelli, Wendy L. Clemens, Glenn S. Kroog, Daniel E. Lopes de Menezes, Chin Pan, Paul D. Ponath, Jean Viallet
  • Patent number: 7858326
    Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: December 28, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
  • Publication number: 20090110659
    Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.
    Type: Application
    Filed: August 1, 2008
    Publication date: April 30, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
  • Publication number: 20090068188
    Abstract: The present invention relates to methods of inhibiting a mammalian C-C chemokine receptor 3 protein (CCR3). The invention further relates to methods of treating an inflammatory disease or condition. Administration of a compound which inhibits or promotes CCR3 function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.
    Type: Application
    Filed: July 11, 2008
    Publication date: March 12, 2009
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackav, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Patent number: 7485301
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 3, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Publication number: 20090011464
    Abstract: The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for ?4?7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for ?4?7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for ?4?7 integrin.
    Type: Application
    Filed: June 18, 2008
    Publication date: January 8, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, Jose Saldanha, Mary M. Bendig
  • Patent number: 7423129
    Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: September 9, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
  • Patent number: 7402410
    Abstract: The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for ?4?7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for ?4?7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for ?4?7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for ?4?7 integrin.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: July 22, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, José Saldanha, Mary M. Bendig
  • Patent number: 7402657
    Abstract: The present invention relates to isolated and/or recombinant C-C Chemokine Receptor 3 (CKR-3, CCR3) proteins or polypeptides.
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: July 22, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Patent number: 7381412
    Abstract: The invention relates to antibodies or antigen-binding fragments thereof which binds the chemokine mammalian TECK and inhibit binding of the chemokine to mammalian GPR-9-6. The invention also relates to host cells that produce such antibodies or antigen-binding fragments, kits comprising such antibodies or antigen-binding fragments and methods of use for such antibodies and antigen-binding fragments.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: June 3, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
  • Patent number: 7285620
    Abstract: The invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to isolated and/or recombinant human eotaxin proteins or polypeptides, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, useful in in vitro methods, diagnosis and/or therapy. Also provided are methods of use of the eotaxin proteins, e.g., in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin, which can be used to selectively modulate leukocyte function, in inflammatory and autoimmune diseases, or in infections.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: October 23, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
  • Patent number: 7265201
    Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to proteins or polypeptides referred to herein as isolated and/or recombinant human eotaxin, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, which are useful in in vitro methods, diagnostic and/or therapeutic applications. Also provided are methods of use of the proteins of the present invention, for example in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used in assays to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin function.
    Type: Grant
    Filed: June 23, 1995
    Date of Patent: September 4, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Shixin Qin, Douglas J. Ringler, Walter Newman, Charles Mackay
  • Patent number: 7147851
    Abstract: The present invention relates to humanized immunoglobulins having binding specificity for ?4?7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human ?4?7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: December 12, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Paul D. Ponath, Douglas J. Ringler, S. Tarran Jones, Walter Newman, José Saldanha, Mary M. Bendig
  • Patent number: 7053202
    Abstract: Featured are DNA molecules, expression vectors, and host cells useful for creation of immunoglobulins, as well as novel immunoglobulin molecules termed monobodies. Additionally provided are methods of production of immunoglobulins, including monobodies, as well as methods of using the disclosed immunoglobulin and monobody constructs, expression vectors and host cells containing DNA encoding molecules for production of immunoglobulin and monobody proteins.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: May 30, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Theresa L. O'Keefe, Paul D. Ponath
  • Patent number: 7012133
    Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: March 14, 2006
    Assignees: Children's Medical Center Corp., Millennium Pharmaceuticals, Inc., Brigham & Women's Hospital
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Patent number: 6994977
    Abstract: The present invention relates to a method of identifying an inhibitor of a mammalian (e.g., human) C—C chemokine receptor 3 (CCR3), comprising combining (a) a compound to be tested, (b) a host cell expressing a recombinant protein comprising a mammalian CCR3, and (c) a ligand of said receptor, under conditions suitable for binding of ligand to said receptor, and detecting or measuring the formation of a receptor-ligand complex. Inhibition of complex formation by the compound is indicative that the compound is an inhibitor.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: February 7, 2006
    Assignees: Children's Medical Center Corporation, Millennium Pharmaceuticals, Inc., Brigham & Women's Hospital
    Inventors: Craig J. Gerard, Norma P. Gerard, Charles R. Mackay, Paul D. Ponath, Theodore W. Post, Shixin Qin
  • Patent number: 6936248
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: August 30, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brain A. Zabel, Paul D. Ponath
  • Patent number: 6884574
    Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: April 26, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath